CA2033200A1 - Vaccinia vectors, vaccinia genes and expression products thereof - Google Patents

Vaccinia vectors, vaccinia genes and expression products thereof

Info

Publication number
CA2033200A1
CA2033200A1 CA002033200A CA2033200A CA2033200A1 CA 2033200 A1 CA2033200 A1 CA 2033200A1 CA 002033200 A CA002033200 A CA 002033200A CA 2033200 A CA2033200 A CA 2033200A CA 2033200 A1 CA2033200 A1 CA 2033200A1
Authority
CA
Canada
Prior art keywords
sal
vaccinia
vaccinia virus
dna
sequences
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002033200A
Other languages
English (en)
French (fr)
Inventor
Geoffrey L. Smith
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Lynxvale Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2033200A1 publication Critical patent/CA2033200A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/7056Lectin superfamily, e.g. CD23, CD72
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/93Ligases (6)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/24011Poxviridae
    • C12N2710/24111Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA002033200A 1989-04-03 1990-04-03 Vaccinia vectors, vaccinia genes and expression products thereof Abandoned CA2033200A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB898907468A GB8907468D0 (en) 1989-04-03 1989-04-03 Vaccinia vectors,vaccinia genes and expression products thereof
GB8907468.6 1989-04-03

Publications (1)

Publication Number Publication Date
CA2033200A1 true CA2033200A1 (en) 1990-10-04

Family

ID=10654377

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002033200A Abandoned CA2033200A1 (en) 1989-04-03 1990-04-03 Vaccinia vectors, vaccinia genes and expression products thereof

Country Status (6)

Country Link
EP (1) EP0465539A1 (de)
JP (1) JPH04504357A (de)
AU (1) AU5350990A (de)
CA (1) CA2033200A1 (de)
GB (1) GB8907468D0 (de)
WO (1) WO1990012101A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5364773A (en) * 1991-03-07 1994-11-15 Virogenetics Corporation Genetically engineered vaccine strain
US5833975A (en) 1989-03-08 1998-11-10 Virogenetics Corporation Canarypox virus expressing cytokine and/or tumor-associated antigen DNA sequence
US7767449B1 (en) 1981-12-24 2010-08-03 Health Research Incorporated Methods using modified vaccinia virus
US6309647B1 (en) 1999-07-15 2001-10-30 Aventis Pasteur Poxvirus—canine dispemper virus (CDV) or measles virus recombinants and compositions and methods employing the recombinants
AU699903B2 (en) * 1990-11-20 1998-12-17 Virogenetics Corporation Measles virus recombinant poxvirus vaccine
US5756102A (en) * 1990-11-20 1998-05-26 Virogenetics Corporation Poxvirus-canine distemper virus (CDV) recombinants and compositions and methods employing the recombinants
AU672581B2 (en) * 1991-03-07 1996-10-10 Virogenetics Corporation Immunodeficiency virus recombinant poxvirus vaccine
US5766598A (en) * 1991-03-07 1998-06-16 Virogenetics Corporation Recombinant attenuated ALVAC canarypoxvirus expression vectors containing heterologous DNA segments encoding lentiviral gene products
DE69233158T2 (de) * 1991-03-07 2004-05-13 Connaught Technology Corp., Greenville Gentechnologisch hergestellter stamm für impfstoffe
ATE298370T1 (de) * 1994-04-29 2005-07-15 Baxter Healthcare Sa Rekombinante poxviren mit fremdenpolynukleotiden in wichtigen regionen
US5858705A (en) * 1995-06-05 1999-01-12 Human Genome Sciences, Inc. Polynucleotides encoding human DNA ligase III and methods of using these polynucleotides
WO2005054451A1 (ja) * 2003-12-05 2005-06-16 Hokkaido Technology Licensing Office Co., Ltd. 高度安全性痘瘡ワクチンウイルスおよびワクシニアウイルスベクター

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0695935B2 (ja) * 1986-07-31 1994-11-30 東燃株式会社 ワクチニアウイルス株

Also Published As

Publication number Publication date
JPH04504357A (ja) 1992-08-06
AU5350990A (en) 1990-11-05
EP0465539A1 (de) 1992-01-15
GB8907468D0 (en) 1989-05-17
WO1990012101A1 (en) 1990-10-18

Similar Documents

Publication Publication Date Title
Niles et al. Vaccinia virus gene D8 encodes a virion transmembrane protein
Hirt et al. Localization and fine structure of a vaccinia virus gene encoding an envelope antigen
Cranage et al. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus.
JP3044062B2 (ja) 組換えポックスウイルス宿主選択系
Bertholet et al. One hundred base pairs of 5'flanking sequence of a vaccinia virus late gene are sufficient to temporally regulate late transcription.
Takahashi-Nishimaki et al. Regulation of plaque size and host range by a vaccinia virus gene related to complement system proteins
AU595190B2 (en) A transcriptional regulatory sequence from the 5'flanking region of the vaccinia virus
US5182210A (en) Fowlpox virus promoters
EP0353851B1 (de) Nichtessentielle Geflügelpockenvirus-Regionen
Bertagnoli et al. Protection against myxomatosis and rabbit viral hemorrhagic disease with recombinant myxoma viruses expressing rabbit hemorrhagic disease virus capsid protein
Tengelsen et al. Nucleotide sequence and molecular genetic analysis of the large subunit of ribonucleotide reductase encoded by vaccinia virus
CA2110489A1 (en) Immunodeficiency virus recombinant poxvirus vaccine
DK175533B1 (da) Vaccine mod rabies samt fremgangsmåde til fremstilling deraf
Colinas et al. Extrachromosomal recombination in vaccinia-infected cells requires a functional DNA polymerase participating at a level other than DNA replication
CA2033200A1 (en) Vaccinia vectors, vaccinia genes and expression products thereof
Wittek et al. Mapping of the genes coding for the two major vaccinia virus core polypeptides
JP3824619B2 (ja) 麻疹ウイルス組換え体ポックスウイルスワクチン
Weir et al. Use of a bacterial expression vector to identify the gene encoding a major core protein of vaccinia virus
EP0699751A1 (de) Dem HCV-genom komplementäre Antisense
WO1992007944A1 (en) Vaccinia vectors, vaccinia genes and expression products thereof
Gong et al. A single point mutation of Ala-25 to Asp in the 14,000-Mr envelope protein of vaccinia virus induces a size change that leads to the small plaque size phenotype of the virus
CA1313151C (en) Vaccine against rinderpest virus using recombinant vaccinia virus
CA2104649A1 (en) Antisense compounds complementary to hcv genome
Cranmer et al. Cloning, characterization, and expression of the murine cytomegalovirus homologue of the human cytomegalovirus 28-kDa matrix phosphoprotein (UL99)
Harty et al. Transcriptional and translational analyses of the UL2 gene of equine herpesvirus 1: a homolog of UL55 of herpes simplex virus type 1 that is maintained in the genome of defective interfering particles

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued